비결핵성 항산균(NTM) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Non-Tuberculous Mycobacterial (NTM) Market Outlook

Thelansis's "Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Tuberculous Mycobacterial (NTM) Overview

Non-Tuberculous Mycobacterial (NTM) pulmonary disease is a chronic, progressive respiratory infection caused by environmental mycobacteria, most commonly Mycobacterium avium complex (MAC) and Mycobacterium abscessus. The disease primarily affects individuals with pre-existing structural lung conditions such as bronchiectasis, cystic fibrosis, and Chronic Obstructive Pulmonary Disease, where impaired airway clearance facilitates persistent infection.

Pathophysiologically, NTM infection drives chronic granulomatous inflammation, leading to progressive lung damage, fibrosis, and functional decline. Diagnosis is complex and requires a combination of clinical symptoms, characteristic radiological findings (e.g., nodular or cavitary lesions on HRCT), and microbiological confirmation.

Treatment is highly challenging due to intrinsic antibiotic resistance and biofilm formation. The current standard of care involves prolonged, multidrug antibiotic regimens-typically macrolide-based-administered for >=12 months post-culture conversion. However, these regimens are associated with significant toxicity, poor tolerability, and high rates of treatment failure or relapse. To address these limitations, the treatment paradigm has evolved toward targeted approaches, including inhaled liposomal aminoglycosides, which enable high local drug concentrations in the lungs while minimizing systemic exposure. Despite these advances, NTM remains a difficult-to-treat condition with substantial unmet need.

Key Highlights

• In Germany, the diagnosed patient pool is projected to increase from 4.4K in 2025 to 4.7K by 2035, reflecting modest growth (0.7% CAGR).
• Treatment remains prolonged and complex, with high rates of toxicity, poor adherence, and frequent relapse, underscoring significant unmet clinical need.
• Increasing focus on inhaled therapies and novel anti-mycobacterial agents is expected to improve treatment outcomes and reshape disease management.

Market Overview

• The Germany NTM market is projected to grow from $104M in 2025 to $132M by 2035, reflecting moderate growth driven by improved diagnosis and adoption of targeted therapies.
• Market expansion is influenced by:
• Uptake of inhaled liposomal therapies and specialized regimens
• Increasing recognition and diagnosis of NTM infections
• Despite modest patient growth (0.7% CAGR), market value is supported by long treatment durations and high-cost therapies.
• Future growth will depend on the development of more effective, better-tolerated therapies that reduce treatment duration and improve cure rates.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Novartis Pharmaceuticals

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)